Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Metrics: Quality vs. Quantify and how the game has changed
Summary
In this episode, Charlie Cook from Takeda joins Tom Caravela to explore the evolving landscape of MSL metrics before, during, and after COVID. They discuss the origins and strategic alignment of these metrics throughout drug lifecycles and the complexities of tracking them across different territories. The conversation delves into the impact of metrics on MSL behavior, emphasizing flexibility in interactions with Key Opinion Leaders (KOLs) and the challenges of a hybrid work environment. Charlie highlights the crucial role of MSL managers in communicating value and evaluating performance. The episode concludes with insights into essential skills for future MSLs, such as emotional intelligence and effective virtual communication.
Charlie Cook, Director MSLs at Takeda, discusses metrics and how the game has changed since Covid 19
Charlie shares….
π His views on Quality vs Quantity
π The importance of focusing on strategic goals
π Advice for the future of Medical Affairs
π Why MSLs need to communicate VALUE
MSL metrics, Medical Science Liaison, COVID impact on MSLs, MSL managers, emotional intelligence
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Podcast
MSL Talk: Tom Caravela
Over-Negotiation-How to Botch a Job Offer
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts KΓ₯gedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary